Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions

被引:29
作者
Campbell, Patrick [1 ]
Symonds, Allison [2 ]
Barritt, A. Sidney [1 ]
机构
[1] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Eshelman Sch Pharm, Dept Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA
关键词
clinical trial; exercise; lifestyle intervention; NAFLD; NASH; CORONARY-HEART-DISEASE; VITAMIN-E; WEIGHT-LOSS; STEATOHEPATITIS; PLACEBO; ATORVASTATIN; EFFICACY; SAFETY; ASSOCIATION; MULTICENTER;
D O I
10.1016/j.clinthera.2021.01.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that is driven by the metabolic syndrome. NAFLD encompasses nonalcoholic fatty liver, >5% fat in the liver without inflammation of fibrosis, nonalcoholic steatohepatitis (NASH), fat plus varying degrees of inflammation and fibrosis, and cirrhosis of the liver from NASH. As facets of the metabolic syndrome, particularly diabetes and obesity, become more common worldwide, the incidence of new NAFLD is increasing. Methods: A qualitative systematic review was performed via searches of PubMed and ClinicalTrials.gov for therapeutic interventions for NAFLD. Findings: Current therapies rely on metabolic syndrome risk factor control and lifestyle changes to achieve weight loss. Because sustained weight loss is difficult for many patients, there is a critical unmet need for pharmacotherapy to treat NAFLD, especially the progressive form, NASH, to prevent cirrhosis of the liver. New therapies for NAFLD focus on the subset of patients with NASH and some degree of fibrosis. Novel mechanisms of action, including farnesoid X nuclear receptor agonism, C-C motif chemokine receptor 2 and receptor 5 antagonism, stearoyl-CoA desaturase-1, and thyroid hormone receptor beta agonism, are currently under investigation as monotherapy. The products also hold potential for use in combination with and without insulin sensitizers and other established drugs in the future. (C) 2021 Elsevier Inc.
引用
收藏
页码:500 / 517
页数:18
相关论文
共 50 条
  • [21] Nutrition and Nonalcoholic Fatty Liver Disease Current Perspectives
    Chakravarthy, Manu, V
    Waddell, Thomas
    Banerjee, Rajarshi
    Guess, Nicola
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2020, 49 (01) : 63 - +
  • [22] Nonalcoholic Fatty Liver Disease: Pharmacologic and Surgical Options
    Parikh, Neil
    Ahmad, Jawad
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2011, 40 (03) : 541 - +
  • [23] The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar, Khurram
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (01) : 57 - +
  • [24] Nonalcoholic Fatty Liver Disease in Children
    Mann, Jake P.
    Valenti, Luca
    Scorletti, Eleonora
    Byrne, Christopher D.
    Nobili, Valerio
    SEMINARS IN LIVER DISEASE, 2018, 38 (01) : 1 - 13
  • [25] CURRENT THERAPIES FOR NONALCOHOLIC FATTY LIVER DISEASE
    Gossard, A. A.
    Lindor, K. D.
    DRUGS OF TODAY, 2011, 47 (12) : 915 - 922
  • [26] Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
    Lee, Hyo Young
    Jun, Dae Won
    Kim, Hyun Jung
    Oh, Hyunwoo
    Saeed, Waqar Khalid
    Ahn, Hyeongsik
    Cheung, Ramsey C.
    Nguyen, Mindie H.
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (02) : 296 - +
  • [27] The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
    Kogiso, Tomomi
    Tokushige, Katsutoshi
    CANCERS, 2021, 13 (03) : 1 - 17
  • [28] Therapeutic options in nonalcoholic fatty liver disease
    Jeffrey L. Tokar
    Carl L. Berg
    Current Treatment Options in Gastroenterology, 2002, 5 (6) : 425 - 436
  • [29] Current and emerging pharmacological therapy for nonalcoholic fatty liver disease
    Ahad Eshraghian
    World Journal of Gastroenterology, 2017, (42) : 7495 - 7504
  • [30] Current and emerging pharmacological therapy for nonalcoholic fatty liver disease
    Eshraghian, Ahad
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (42) : 7495 - 7504